Wegovy and Possible Vision Risk - Scorecard - MDSpire

Wegovy and Possible Vision Risk

Higher dose weight loss injectable demonstrates nearly five times higher ischaemic optic neuropathy risk than other semaglutide GLP-1 agonists

  • April 8, 2026

  • 3 min

Share

Clinical Scorecard: Wegovy and Possible Vision Risk

At a Glance

CategoryDetail
Condition
Key MechanismsPotential link between high-dose semaglutide and optic nerve ischaemia due to rapid weight loss and metabolic shifts, as suggested by observational data.
Target Population
Care Setting

Key Highlights

  • Semaglutide associated with significant signal for ION, particularly with Wegovy formulation, with a reported risk nearly five times higher than Ozempic.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular eye examinations for patients on high-dose semaglutide, ideally every 6 months.

      Risks

        Patient & Prescribing Data

        Individuals with type 2 diabetes and obesity prescribed GLP-1RAs.

        Wegovy may pose a higher risk for ION compared to other formulations.

        Clinical Best Practices

        • Implement routine eye screenings for patients on high-dose semaglutide every 6 months.

        References

        Original Source(s)

        Wegovy and Possible Vision Risk

        • April 8, 2026

        Related Content

        Comparative study of the therapeutic effects of different medications on DM-associated dry eye syndrome after vitrectomy

        Diabetes Risk Scores: Beyond Glucose

        Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

        A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues